Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 8/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574954 | 0.91 | S1PR2 (0.53) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1575357 | 0.88 | S1PR2 (0.52) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1575303 | 0.88 | S1PR2 (0.52) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1574590 | 0.88 | FAAH (0.50) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1574940 | 0.87 | GRIN2B (0.55) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1574517 | 0.85 | HPGD (0.55) | FAAHGRIN2BKDM4EHTTALDH1A1 | |
| SCHEMBL1574543 | 0.84 | GRIN2B (0.52) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1575126 | 0.84 | S1PR2 (0.53) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1575185 | 0.84 | S1PR2 (0.51) | S1PR2FAAHGRIN2BKDM4EPKM | |
| SCHEMBL1574828 | 0.82 | ALDH1A1 (0.59) | FAAHGRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | S1PR2 937/4885FAAH 3484/4885GRIN2B 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.